INST 0601C: A randomized phase II protocol of erlotinib versus standard platinum-based chemotherapy in patients with newly diagnosed, advanced non-small cell carcinoma of the lung.

Trial Profile

INST 0601C: A randomized phase II protocol of erlotinib versus standard platinum-based chemotherapy in patients with newly diagnosed, advanced non-small cell carcinoma of the lung.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs Erlotinib (Primary) ; Antineoplastics; Platinum complexes
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Aug 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 25 May 2012 Actual end date changed from 1 Jul 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top